ADUS stock forecast, quote, news & analysis
Addus HomeCare Corp is engaged in the provision of in-home care services... Show more
Why Addus HomeCare (ADUS) Stock Is Up +16% in the Last 30 Days
Key Takeaways
- Addus HomeCare (ADUS) surged approximately 16% over the last 30 days, rising from $100.47 on June 30, 2026, to $116.32 as of July 30, 2026.
- Over the broader quarter, ADUS climbed roughly 20% from $96.89 at the end of April, rebounding sharply after hitting a 52-week low of $87.95 in early June.
- The rally has been fueled by strong Q1 2026 earnings, expansion into Indiana through acquisitions, improving personal care census trends, and favorable analyst commentary.
- Upcoming Q2 2026 earnings, scheduled for release on August 3, represent the next major catalyst for the stock.
- Wall Street maintains a consensus "Moderate Buy" rating with a $131.50 average price target, suggesting continued upside potential from current levels.
Addus HomeCare (ADUS) Company Overview and Market Position
Addus HomeCare Corporation is a leading provider of home and community-based care services across the United States, serving approximately 62,750 patients and consumers through 263 locations in 24 states. The company operates through three primary segments: Personal Care (77.3% of Q1 2026 revenue), which provides non-medical assistance with activities of daily living; Hospice (18.1% of revenue), delivering end-of-life physical, emotional, and spiritual care; and Home Health (4.6% of revenue), offering skilled nursing and therapy services. Addus primarily serves elderly, chronically ill, and disabled individuals whose payors include federal and state agencies, managed care organizations, commercial insurers, and private individuals. Investors follow ADUS closely because of its role in the growing shift toward cost-effective home-based healthcare, favorable demographic tailwinds, and a disciplined acquisition strategy that expands both geographic reach and service density.
Addus HomeCare (ADUS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ADUS shares have surged approximately 16%, climbing from a closing price of $100.47 on June 30, 2026, to an intraday price of $116.32 on July 30, 2026. The stock built momentum steadily throughout July, breaking above the psychologically important $110 level in mid-July and reaching as high as $120.61 before pulling back slightly in the final days of the month.
The quarterly picture tells an even more compelling recovery story. At the end of April, ADUS closed at $96.89. The stock then endured a volatile stretch in May and early June, dropping to a 52-week low of $87.95 on June 3 amid broader market uncertainty and post-earnings consolidation. From that trough, ADUS has staged a powerful rebound of approximately 32% to current levels, reflecting renewed investor confidence in the company's growth trajectory. The quarter-to-date gain of roughly 20% underscores the strength of the recent rally.
What Drove ADUS Stock Price in the Last 30 Days
Several catalysts have powered ADUS shares higher over the past month. The company's first-quarter 2026 earnings, reported on May 4, continued to resonate with investors as the market digested the strong results: net service revenues rose 7.7% year-over-year to $363.6 million, while adjusted net income per diluted share jumped 14.1% to $1.62, surpassing consensus estimates of $1.52. Adjusted EBITDA also grew 9.7% to $44.5 million.
Investor sentiment received an additional boost from the company's expansion into Indiana through the acquisition of HomeCourt Home Care's personal care operations, which closed May 1, along with a definitive agreement for a second Indiana acquisition. During the RBC Capital Markets Global Healthcare Conference in May, CEO Dirk Allison and CFO Brian Poff provided upbeat commentary on improving personal care census trends, the successful rollout of the caregiver mobile app in key states, and a robust M&A pipeline—all of which supported the bullish narrative.
On the analyst front, Weiss Ratings upgraded ADUS from "hold (c-)" to "hold (c)" on July 9, while consensus price targets remain well above current trading levels. The company's July 20 announcement that Q2 2026 earnings would be released on August 3 generated further anticipation, as investors positioned ahead of what could be another strong quarter. The broader healthcare services sector has also benefited from defensive positioning and steady demand visibility, providing a favorable backdrop for the stock's advance.
What Drove ADUS Stock Performance Over the Last Quarter
The quarterly trend reflects a classic "dip and recovery" pattern driven by a combination of fundamental strength and temporary headwinds. After reporting better-than-expected Q1 results in early May, ADUS shares initially traded higher but then pulled back through mid-May and early June. This weakness coincided with a broader risk-off sentiment that affected mid-cap healthcare names, as well as concerns around a new federal moratorium on certain home health licenses and ongoing CMS regulatory scrutiny.
However, management effectively addressed these concerns during the RBC conference, clarifying that the moratorium applies only to de novo clinical home health licenses—not to personal care services, which represent the bulk of Addus's acquisition activity. The company also highlighted improving census trends in key states like Illinois, Texas, and New Mexico, along with the caregiver app's positive impact on fill rates. These operational tailwinds, combined with a strong balance sheet featuring $103.1 million in cash against $94.3 million in debt and $547.8 million in revolver availability, gave investors confidence that Addus can continue executing on both organic growth and M&A. The stock's recovery from its June lows reflects the market's recognition that the underlying business remains on solid footing.
Trending AI Robots
For traders seeking to complement their fundamental analysis with data-driven signals, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered bots that trade across thousands of tickers, but only the most relevant and highest-performing strategies appear in this dynamically updated section. These bots vary widely in terms of trading style, holding period, and performance metrics, allowing users to find approaches aligned with their own risk tolerance and objectives. Whether you are looking for short-term momentum plays or longer-duration trend-following strategies, the Trending AI Robots section provides a convenient starting point to explore algorithm-driven trading ideas.
ADUS Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst for ADUS is the upcoming Q2 2026 earnings release on August 3, 2026, followed by the conference call on August 4. Investors will closely monitor same-store personal care hours growth, hospice average daily census trends, and any updates on the Indiana integration and M&A pipeline. Management's commentary on state reimbursement rates—particularly any developments in New Mexico's incremental funding allocation and Illinois budget discussions—will be critical for the forward outlook.
Longer-term, the aging U.S. population and the ongoing shift toward home-based care provide a durable secular growth tailwind. However, regulatory risk remains a factor worth watching, particularly CMS scrutiny of fraud and abuse in home health and hospice. The company's ability to sustain organic revenue growth in the 3% to 5% range and deploy its strong balance sheet toward accretive acquisitions will largely determine whether the stock can maintain its momentum toward the consensus analyst price target of $131.50. Competitive pressures in personal care and potential changes to state Medicaid funding also merit ongoing attention.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ADUS saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for ADUS moved out of overbought territory on July 31, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 63 similar instances where the indicator exited the overbought zone. In of the 63 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ADUS moved out of overbought territory on July 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ADUS broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The 10-day moving average for ADUS crossed bullishly above the 50-day moving average on June 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADUS advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 195 cases where ADUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.931) is normal, around the industry mean (229.491). P/E Ratio (21.306) is within average values for comparable stocks, (124.040). Projected Growth (PEG Ratio) (1.109) is also within normal values, averaging (1.762). ADUS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (1.470) is also within normal values, averaging (2.631).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of home and community based services
Industry HospitalNursingManagement